Профиль компании · Healthcare

Johnson & Johnson

JNJ · США
Отрасль
Pharmaceuticals
Биржа
США
Страна / Регион
USA
Дата IPO
24 сентября 1944 г.
Сотрудники
138 200
Сайт
www.jnj.com
Текущая цена
$265.95
В реальном времени · 27 июля 2026 г.
Балл роста Baillie
48/100
Слабоватый
Внутренняя стоимость · три уровня Текущая цена $265.95 Онлайн · Выше оптимистичного потолка · будущий рост уже исчерпан

Сводный диапазон оценки · консервативный $120–$150 / справедливый $150–$190 / оптимистичный $190–$230. При $265.95, Выше оптимистичного потолка · будущий рост уже исчерпан.

На момент публикации $234.34 (25 мая 2026 г.)

Капитализация634,77 млрд $
Выручка (TTM)97,93 млрд $
EBITDA34,84 млрд $
Чистая маржа21,48 %
ROE26,42 %
P/E (TTM)30,14
Прогнозный P/E22,27
PEG4,29
Прибыль на акцию8,74 $
Дивидендная доходность2,02 %
Диапазон за 52 недели160,21 $ – 269,43 $
Целевая цена аналитиков270,59 $
Рейтинг аналитиков3.8 / 5

Данные EODHD, показаны в валюте отчётности; только для справки, не является инвестиционной рекомендацией.

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

История

Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey, with an IPO date of September 24, 1944. The company no longer includes its consumer health business, which was separated through the Kenvue spin-off, and is now organized around two segments: Innovative Medicine and MedTech. In 2026 the company achieved its 64th consecutive year of dividend increases.

Положение в отрасли

Johnson & Johnson is a healthcare company in the Drug Manufacturers - General industry, operating worldwide with about 138,200 employees. In 2025 it reported total sales of roughly $94.2 billion, split between Innovative Medicine at about $60.4 billion and MedTech at about $33.8 billion. The company has disclosed that over 75% of its sales come from categories ranked first or second in global market share, and that it has 28 platforms each exceeding $1 billion in annual sales.

Аналитики по этой бумаге на вашем языке пока нет.